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Aims and method Depression in first-episode psychosis (FEP) is highly prevalent
and associated with poor outcomes; it has become increasingly recognised and
adopted in national and international guidelines for psychosis. Using a 26-item
questionnaire, this study aimed to explore if this shift has led to greater recognition
among UK psychiatrists, and more effective management of depression in FEP.
Results Of the 297 respondents, 54.4% observed depression occurring in chronic
psychosis, with the least number of respondents (17.7%) identifying depression
occurring frequently during FEP. Although there was reasonable agreement in the use
of antidepressants as a first-line treatment for depression (70% prescribing
antidepressants), there was uncertainty around assessing depression and delineating
from psychosis symptoms, and particularly negative symptoms.
Clinical implications Evidence-based treatments for comorbid depression in psychosis
will lead to clearer national guidelines, allowing for optimal management of depression in
early psychosis, potentially leading to improved outcomes for these individuals.
Keywords Comorbidity; psychotic disorders; antidepressants; depressive disorders;
early intervention.
Depression is prevalent in first-episode psychosis (FEP), with
rates of up to 70%at illness onset.1 It is associatedwith a higher
risk of relapse,2 poorer functional outcomes3,4 and suicide.5
Although the National Institute for Health and Care
Excellence (NICE) recommends monitoring for depression
within psychosis, specific guidance on the treatment of
comorbid depression has been limited, until recently.6,7 The
lack of large-scale controlled trials investigating the effective-
ness of adjunctive antidepressants8 has perhaps resulted in
considerable variation in prescribing practices.6,9 A study of
80 000 international psychiatrists showed little consensus on
the best management strategy for treating depression in
schizophrenia; a third of clinicians reported that they rarely
or never prescribe antidepressants in combination with
antipsychotics.9,10 Since this publication in 2001,9 depression
as a common occurrence in psychosis has becomemore widely
recognised.11,12 Monitoring for depression in psychosis is
featured more commonly in national and international
guidelines,7 and the recent British Association for
Psychopharmacology updated consensus statement is the first
UK guide to include specific pharmacological treatment
recommendations.13
We aim to understand whether there has been an
improvement in clinician awareness of depression in psych-
osis; this may have an impact on effective management, par-
ticularly in the early stages of psychosis, where treatment is
likely to be more effective.14 Using a survey which was dis-
tributed to UK psychiatrists, this study aimed to explore
the level of recognition and management of depression
through the course of FEP.
Method
Participants
Participants were members of the Royal College of
Psychiatrists, which is a professional organisation of psychia-
trists based in the UK. The sample therefore comprised psy-
chiatrists of various ages and career stage, from those in
training to consultant level. Although there are around 8700
psychiatrists registered at the Royal College of Psychiatry,
the survey was targeted at, and only distributed to, the general
adult faculty. Participants were given the opportunity to enter
into a prize draw to win £200 worth of Amazon vouchers.
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Measures
Management of Depression in Psychosis questionnaire
The Management of Depression in Psychosis questionnaire
is a shortened version of Siris et al’s original questionnaire.9
It was felt to be the most suitable as it was designed to evalu-
ate clinician awareness and management approach. It also
allows for comparison of trends of psychiatric practices in
assessing and managing depression in psychosis over time.
The questionnaire has been adapted to focus on the identi-
fication of depression and prescribing in the early course
of psychosis. For the purpose of this study, recognition of
depression is defined as assessing for the three cardinal
symptoms of depression, namely low mood, anhedonia and
anergia. The questionnaire was built into Survey Monkey
for ease, practicality and anonymous online administration.
The questionnaire was completed anonymously and com-
prised 23 questions relating to the following: demographic
characteristics of the respondents (e.g. gender, years since
graduation, specialty/subspecialty and region of practice);
recognition of symptoms relevant to the diagnosis of depres-
sion; depression time course in psychosis; factors and symp-
toms that prompt the prescription of antidepressants;
evaluation measures; and treatment selection and practice
(e.g. medication dose and duration).
Procedure
The questionnaires were completed over a period of 2
months after being granted ethical approval and agreed
sponsorship by University of Birmingham (REC Reference:
ERN_18-1658). Participants were provided with information
about the study, informed of the voluntary nature of their
participation, and reminded that responses were anonymous
with the option to opt in for the prize draw. Written
informed consent was obtained from all participants.
Data analysis
Data were downloaded from Survey Monkey (see http://www.
surveymonkey.co.uk/r/Depression_in_psychosis_survey) and
inspected using a Microsoft Excel (365 for Windows) work-
sheet. Descriptive statistics were explored using SPSS version
24 for Windows.
Results
In total, there were 297 respondents; although on average, it
was observed that a third of the participants who completed
the survey also skipped at least one question in the question-
naire. A total of 52% were male, and on average, the sample
had 21 years (s.d. 11.5) of practice since graduating from
medical school. Responses by geographical regions were as
follows: London (13.4%), South-East (12.4%), West
Midlands (11.9%), South-West (11.9%) and Scotland
(11.9%). We had the least responses from Wales (2.6%),
Northern Ireland (2.6) and East Midlands (3.6%), and
26.8% of participants did not give a response. The majority
of the respondents were clinicians that practiced within
community settings (67.7%).
Observed prevalence and time course of depression in
psychosis
A total of 41.2% of participants had a case-load of which
patients with psychosis comprised >50%; 46.6% had
between 5–50% and 1.3% had <5%. The majority of respon-
dents reported observing depression occurring concurrently
with chronic stable psychosis (54.4%), and 23% reported
depression occurring concurrently with acute relapse. With
regards to depression emerging in the initial phase of illness,
19.1% observed depression within the prodromal phase to
the acute psychotic phase; 32.4% reported depression emer-
ging as the first acute episode of psychosis resolves, and
17.7% of respondents reported observing depression during
the first episode of psychosis.
Assessment and diagnosis of depression in psychosis
Respondents were asked to select the first five most relevant
symptoms they consider in diagnosing depression in psych-
osis: 93.2% identified low mood, 68.3% identified anhedonia,
57.1% identified suicidal thoughts, 53.2% identified poor
motivation and 48.3% identified interest in life as a symp-
tom. Please see Fig. 1 for the full breakdown of symptoms
reported by respondents.
The majority of participants reported not utilising a
specific interview system to inform a diagnosis of depression
in psychosis (96.6%). In terms of employing depression
evaluation measures, 35.1% of respondents reported using
none, 39.1% used the Beck Depression Inventory, 28.5%
used the Hamilton Rating Scale for Depression, 17.2% used
the Brief Psychiatric Scale and 9.3% used the Calgary
Depression Scale for Schizophrenia (CDSS).
Recognition and management of depression in
psychosis
Participants were asked about which clinical guidelines they
used to aid the recognition and management of depression
in psychosis: 61.5% of respondents used NICE guidelines,
50.0% used the Maudsley Prescribing Guidelines, 27.6%
used British Association for Psychopharmacology guidelines
and 12.0% used BJPsych Advances (previously known as
Advances in Psychiatric Treatment) articles; the remainder
mainly used clinical experience.
Treatment approaches
Antidepressant therapy
The majority of respondents reported that antidepressant
medication would be their first line of treatment for psych-
osis with comorbid depression (69.5%), 32.5% indicated cog-
nitive–behavioural therapy, 12.3% reported a ‘watch and wait
approach’ and 7.4% would reduce the dose of the prescribed
antipsychotic medication.
In terms of factors that would prompt prescribing of an
antidepressant, 84.2% reported a family history of depres-
sion, 40.4% reported poor interpersonal and social skills,
39.2% reported ‘living alone’ and 29.8% reported a ‘recent
loss or rejection’. Key symptoms prompting a prescription
of an antidepressant medication included hopelessness
(80.1%), low mood (76.5%) and suicidal ideation (75.5%).
2
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With regards to antidepressants prescribed in early
psychosis with comorbid depression, selective serotonin
reuptake inhibitors were generally preferred; the majority
of respondents opted for sertraline (85.4%), followed by mir-
tazapine (49.8%), fluoxetine (45.4%) and venlafaxine
(33.7%). Interestingly, 28.8% of participants opted for citalo-
pram and 15.1% opted for escitalopram. Please see Fig. 2 for
the proportions of antidepressants prescribed.
Antipsychotic therapy
Participants were asked about antipsychotics they routinely
prescribe for young people with early psychosis. Atypical
antipsychotic agents were the most commonly prescribed:
66.0% of respondents opted for aripiprazole, 54.2% opted
for olanzapine, 52.2% opted for risperidone and 44.3%
opted for quetiapine. Clozapine was selected by 9.9% of
respondents. Please see Fig. 3 for the proportion of antipsy-
chotics prescribed.
Drug combinations and treatment duration
In terms of conjunctive antidepressant anddopamine antagon-
ist prescribing, 55.7% reported they would not frequently pre-
scribe this combination, 35.8% reported often prescribing and
8.5% affirmed that they very often prescribe this combination.
A total of 13.5% of respondents stated that they would
completely avoid mirtazapine and olanzapine in
Fig. 2 Proportions of antidepressants
reported to be prescribed as first-line




























Fig. 1 Breakdown of main symptoms identified
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combination, with a handful citing reasons such as weight
gain and oversedation; 14.4% stated they would actively
avoid citalopram and antipsychotics in combination, with
some citing reasons such as increased risk of corrected QT
interval prolongation; and 42.3% reported that there were
no combinations that they would actively avoid.
With regards to duration of therapy, 47.8% of respon-
dents estimated expecting clinical benefits within 2–4
weeks of adding antidepressant to dopamine antagonist
therapy, 43.3% thought it would likely take 4–6 weeks and
7.5% predicted improvement in 6–12 weeks. The majority
of participants (77.5%) felt that antidepressant therapy
should continue for 6–12 months once the individual showed
a satisfactory response, 15.7% felt that therapy should
continue for >12 months and 8.3% felt that therapy
should continue for 3–6 months. In terms of physical health
monitoring when coprescribing, 77.9% monitored heart
rhythm via electrocardiogram, monitored blood chemistry
(prolactin, glucose and lipid profile), 73.4% monitored
bloods (prolactin, glucose and lipid profile) and 42.9%
undertook a physical examination. However, 18.2%
reported that no physical health interventions were
carried out.
Non-pharmacological treatment approaches
On average, most respondents prescribed non-pharmacological
therapies for depression in FEP, with 82.1% opting for psy-
choeducation and cognitive–behavioural therapy, 67.2% opting
for psychosocial interventions and 42.3% opting for family
interventions. A further 10.5% of participants reported pre-
scribing electroconvulsive therapy, and a handful opted for life-
style interventions and supportive psychotherapy.
Reflections from respondents
Overall, about a third of the participants highlighted diffi-
culty in delineating negative symptoms of psychosis from
depression during a period of psychosis. Others described
the complex interactions of positive and cognitive symptoms
that are hard to disentangle, as well as the possibility of an
affective illness occurring as the primary driver for psych-
osis. Many respondents expressed keenness in offering
psychology or psychotherapy, but cited problems with avail-
ability at the time of need.
Discussion
This study aimed to gauge the level of recognition and manage-
ment approaches used by UK psychiatrists to manage and treat
depression in psychosis. With depression in psychosis now
being adopted in national and international clinical guide-
lines,7 we wanted to explore whether any change in recognition
has led to more effective management of depression in those
with psychosis, particularly in the early stages of illness.
Overall, the majority of respondents (69.5%) indicated
the use of antidepressant medication as a first line of treat-
ment for young people with psychosis and comorbid depres-
sion. There was reasonable agreement among clinicians on
the contextual factors and key symptoms that would prompt
a prescription of antidepressant medication. For example, the
majority of respondents reported low mood and anhedonia as
the major symptoms for diagnosing depression (93% and
68%, respectively), with 45% also identifying anergia as a
core symptom. Over 80% of participants reported that they
would routinely prescribe a selective serotonin reuptake




























Fig. 3 Proportions of antipsychotics prescribed by respondents.
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agreement between clinicians on the best strategy for man-
aging comorbid depression with psychosis. These findings
demonstrate a possible shift in the management strategy
since Siris et al’s9 earlier publication, where a third of clini-
cians reported that they would rarely prescribe antidepres-
sants in adjunct to antipsychotic medication.
Although previous studies have reported 70% preva-
lence rates of depression at illness onset,1 our study showed
fewer respondents (19%) identified depression as occurring
frequently in FEP; instead, 54% reported observing depres-
sion occurring with stable psychosis. This might suggest
that depression in the early phases of psychosis is still
underrecognised; this is concerning, given that young people
in particular are at heightened risk of suicide within the first
12 months following the initial episode of psychosis.15,16
However, it must also be acknowledged that the findings
from our survey are reliant on the memory of clinicians,
with a potential for recall bias, and so the accuracy of
these findings may be challenged.
Despite a consensus on treatment strategies for depres-
sion, what became apparent from the survey was the uncer-
tainty around assessing depression and delineating from
psychosis symptoms, and particularly negative symptoms.
Interestingly, a large proportion do not employ structured
interview schedules to inform their assessment, which
could aid this delineation. In particular, the CDSS was
only used by 9% of respondents. The CDSS is a short and
easily used instrument, designed specifically for the assess-
ment of depression in psychosis, as it distinguishes between
negative and positive symptoms.17 Better promotion of these
evaluation measures may be warranted.
There were also reports of challenges faced by clinicians
in determining if the symptoms were part of an affective
component of the psychotic episode, potentially highlighting
the need for a better understanding of the diagnostic uncer-
tainty and course of depression in early psychosis.18
Over the past two decades, there appears to have been a
shift in prescribing of antipsychotic medications – particu-
larly from the first generation (typical) to second generation
(atypical) agents.19 This is also reflected in our survey, where
the majority were prescribing atypical agents such as aripi-
prazole, olanzapine, risperidone and quetiapine, compared
with 4.9% and 3.9% of respondents prescribing haloperidol
and zuclopenthixol. Thus, there appears to be a particular
preference toward the antipsychotics believed to have the
least side-effects, but not with recognition that some anti-
psychotics may have more antidepressant properties,20 or
possibly promote depression, such as haloperidol.13
In regards to coprescribing in the present study, most
respondents reported that there were no combinations of
antidepressants and antipsychotics that they would actively
avoid; however, some did express actively avoiding citalo-
pram and antipsychotic in combination, with some citing
risk of prolongation of the corrected QT interval. A similar
percentage reported they would actively avoid a combination
of mirtazapine and olanzapine because of increased risk of
weight gain and sedation. In line with this, the majority of
respondents (>70%) stated that they provided routine phys-
ical health monitoring when coprescribing. These findings
indicate that clinicians are perhaps more cognisant of the
potential physical health problems caused by antipsychotic
medications, and may suggest proactiveness in mitigating
such risks. Although this finding is encouraging, recent
data shows that only 32.3% of individuals with severe mental
illness in England receive a full physical health check.21,22
Given the lowered life expectancy of individuals with schizo-
phrenia, the current NICE recommendations advocate for
annual physical health checks for all individuals with severe
mental health problems.23 Improving physical health moni-
toring should remain a top priority.22
Implications for clinical practice
Our results may indicate further training and embedding of
routine assessment tools into clinical practice is be needed
to further increase the recognition and management of
depression, which, if achieved, could improve outcomes.
Indeed, this finding is in keeping with the wider literature
on the difficulty of promoting the use of instruments, such
as the CDSS, into routine practice.24 A suggestion may be
to embed these instruments into electronic patient records,
and include monitoring of comorbidities as part of quality
improvement programmes, and national audits such as the
National Clinical Audit of Psychosis.25
Study strengths and limitations
This study was the first to explore clinician recognition and
management of depression in young people with FEP.
Although the survey was completed by 297 clinicians,
responses were underrepresented in certain parts of the
country (particularly Wales, Northern Ireland and East
Midlands), and overall response rate was low. On average,
a third of the participants who completed the survey also
returned incomplete questionnaires, affecting the overall
representativeness of the information provided.
This study relied on the clinician reflecting on their pre-
vious practice, awareness and general approach, and they
were provided with multiple options for each question. As
such, there is a potential for recall bias. Furthermore,
some questions were focused on depression within psychosis
more generally, meaning that responses were less specific to
depression in FEP. It is also very likely that clinicians within
the Early Intervention Service and those with more interest
in this field may have been more involved in the survey. An
Amazon voucher was also offered as an incentive for partici-
pation, again, further introducing a respondent bias.
Another limitation was in disseminating the survey.
Because of regulations governing the Royal College of
Psychiatry, emails were only distributed to members regis-
tered under the General Adult Psychiatry faculty. The ques-
tionnaire was not disseminated to other psychiatric
disciplines that may have been relevant, such as Child and
Adolescent Mental Health Service, and Forensic or
Learning Disability subspecialties. Finally, the survey was
UK-based, with a low response rate. Further research is
required to understand whether these practices are uniform
in a larger sample of participants, and across different coun-
tries, particularly in the USA and Europe.
In conclusion, although there is now more consensus on
recognising depression in early psychosis strategies, there
continues to be variations in the approach toward its
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assessment and management (e.g. in the use of specific
interview schedules or evaluation measures to assess depres-
sion in those with psychosis). Although our findings are ten-
tative, given the low response rate, the survey indicates that
adjunctive treatment is being administered by most clini-
cians; however, some expressed difficulties in differentiating
between depression occurring in relation to psychosis and
negative symptoms of psychosis, and there was little consen-
sus on treatment duration and time of expectation of
response. Embedding of structured assessment tools into
routine practice, in addition to devising clearer national
guidelines based on large definitive trials, would be instru-
mental in improving future practice in early psychosis,
potentially leading to improved outcomes.
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